Welcome to our dedicated page for Nautilus Biotechnology news (Ticker: NAUT), a resource for investors and traders seeking the latest updates and insights on Nautilus Biotechnology stock.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) is a development stage life sciences company developing a single-molecule proteome analysis platform, and the news surrounding NAUT often centers on progress toward validating and deploying this technology. The company’s communications highlight its Iterative Mapping method, tau proteoforms assay, and collaborations with leading research institutions as key themes in its news flow.
Readers following Nautilus news can expect updates on platform development milestones, such as the successful installation and testing of the first external field evaluation unit at the Buck Institute for Research on Aging. News has described how researchers at the Buck Institute generated highly reproducible tau proteoform data from neurodegenerative disease samples and used the Nautilus Proteome Analysis Platform to explore region-specific proteoform patterns associated with disease progression.
NAUT news also covers agreements and collaborations, including an agreement with the Allen Institute focused on investigating the connection between tau protein and neurodegenerative conditions such as Alzheimer’s disease. These announcements often discuss efforts to identify novel tau proteoforms, quantify their prevalence, and characterize phosphorylation patterns that may help explain disease course.
Financial results and corporate updates are another important category of Nautilus news. The company regularly issues quarterly earnings press releases describing operating expenses, net loss, cash, cash equivalents, and investments, along with commentary on development progress and plans for its platform and Early Access Program. Investors can also find notices about upcoming earnings calls, participation in healthcare and investor conferences, and regulatory filings reported via Form 8-K.
In addition, Nautilus has announced an Early Access Program for its proteomics platform, starting with a tau proteoforms assay, which is a recurring topic in its news. These articles explain how selected researchers gain access to the Iterative Mapping method, receive support for data interpretation and analysis, and participate in custom assay development partnerships. For anyone tracking NAUT, this news page provides a centralized view of technology, collaboration, commercialization, and financial developments related to the company’s single-molecule proteomics efforts.
Nautilus Biotechnology (NASDAQ: NAUT) reported Q1 2026 results and business progress for the quarter ended March 31, 2026. Key highlights include launching an Iterative Mapping Early Access Program with Baylor College of Medicine as the first customer, appointment of Amber Faust as VP of Global Sales, and platform development for a next-generation assay.
Financials: Operating expenses were $16.1M, down 14% year-over-year; net loss was $14.7M versus $16.6M a year earlier; cash and investments totaled $143.4M as of March 31, 2026.
Nautilus Biotechnology (NASDAQ: NAUT) will report first quarter 2026 financial results before market open on April 28, 2026. Management will host a webcast and conference call at 5:30 a.m. PT / 8:30 a.m. ET to discuss results, business developments, and outlook. Live audio will be available on the company Investors website.
Nautilus Biotechnology (NASDAQ: NAUT) will participate in the Investor Summit Group Virtual Conference. Management is scheduled to present on Wednesday, March 25, 2026 at 10:00 a.m. PT / 1:00 p.m. ET. Live and archived webcasts will be available in the Investors section of the company website.
Investors can access the webcast at www.nautilus.bio.
Nautilus Biotechnology (NASDAQ: NAUT) named Baylor College of Medicine its first customer for the Iterative Mapping Early Access Program on March 18, 2026. Baylor will use the Nautilus Voyager™ Platform in an NIH U01-funded study to develop a computational multi-omics toolkit for high-resolution cancer isoform analysis.
The collaboration pairs Baylor’s computational expertise with Nautilus’ single-molecule proteomics and validated tau proteoforms assay to improve detection and quantification of protein isoforms and enable direct transcriptional–proteomic comparisons.
Nautilus (NASDAQ: NAUT) appointed Amber Faust as Vice President of Sales to lead commercialization of the Nautilus Voyager™ Platform.
The hire follows the public debut of Voyager and launch of the Iterative Mapping Early Access Program; Nautilus plans to initiate commercial launch of Voyager in late 2026.
The company’s first assay, Tau Proteoforms, is already in active use at the Buck Institute.
Nautilus Biotechnology (NASDAQ: NAUT) reported Q4 and fiscal 2025 results on Feb 26, 2026. Operating expenses fell to $15.4M in Q4 and $66.8M for FY2025, while net loss was $13.8M in Q4 and $59.0M for FY2025. Cash and investments totaled $156.1M as of Dec 31, 2025.
The company launched an Iterative Mapping Early Access Program in Jan 2026, advanced platform validation with Tau proteoform data, and initiated a Michael J. Fox Foundation–supported collaboration for alpha-synuclein assays. Nautilus expects no material Early Access revenue in 2026 and forecasts operating expense growth of 15–20% year over year, believing cash suffices to fund operations through 2027.
Nautilus Biotechnology (NASDAQ: NAUT) unveiled the Voyager™ Platform at US HUPO 2026, a benchtop system designed to enable Iterative Mapping of up to 10 billion intact proteins and proteoforms in a single run. The company began an Early Access Program in Jan 2026 and expects commercial launch in late 2026.
Field evaluation at the Buck Institute produced reproducible tau proteoform insights; initial offerings include a Tau Proteoforms assay quantifying up to 768 full-length tau proteoform groups. Limited instrument placements will precede broad commercial availability.
Nautilus Biotechnology (NASDAQ: NAUT) will participate in the TD Cowen 46th Annual Health Care Conference. Management is scheduled for a fireside chat on March 2, 2026 at 10:30 a.m. ET. A live and archived webcast will be available on the company Investors website at www.nautilus.bio.
Nautilus Biotechnology (NASDAQ: NAUT) will report fourth quarter and full year 2025 financial results before market open on Thursday, February 26, 2026. Management will host a webcast and conference call to discuss results, business developments, and outlook.
Live audio will be available on the company’s Investors webpage at www.nautilus.bio.
Nautilus Biotechnology (NASDAQ: NAUT) announced a research collaboration with Weill Cornell Medicine-Qatar and The Michael J. Fox Foundation supported by a $1.6 million MJFF grant to develop a single-molecule assay measuring alpha-synuclein proteoforms for Parkinson’s disease biomarker research.
The project pairs Nautilus’ Iterative Mapping single-molecule proteomics platform with Lashuel lab expertise to probe post-translational modifications and enable improved disease detection, stratification, and monitoring.